The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. - Wikidata - wikimedia - TriplyDB

The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin.

The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin.

http://www.wikidata.org/entity/Q40851439

about

Drug interactions--principles, examples and clinical consequences Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St. John's wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor.Renal drug transporters and their significance in drug-drug interactions Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin Simultaneous measurement of in vivo P-glycoprotein and cytochrome P450 3A activities Saint John's wort: an in vitro analysis of P-glycoprotein induction due to extended exposure Prediction of promiscuous p-glycoprotein inhibition using a novel machine learning scheme Development of novel rifampicin-derived P-glycoprotein activators/inducers. synthesis, in silico analysis and application in the RBE4 cell model, using paraquat as substrate The Interactions of P-Glycoprotein with Antimalarial Drugs, Including Substrate Affinity, Inhibition and Regulation Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers.Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data.How Does In Vivo Biliary Elimination of Drugs Change with Age? Evidence from In Vitro and Clinical Data Using a Systems Pharmacology Approach.Pharmacokinetic interactions of drugs with St John's wort.Evaluation of CYP3A-mediated drug-drug interactions with romidepsin in patients with advanced cancer.Pharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers.Intestinal permeability of metformin using single-pass intestinal perfusion in rats.ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2.A novel method using confocal laser scanning microscopy for sensitive measurement of P-glycoprotein-mediated transport activity in Caco-2 cells.Vanadate trapping of nucleotide at the ATP-binding sites of human multidrug resistance P-glycoprotein exposes different residues to the drug-binding site Macrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin How to manage individualized drug therapy: application of pharmacogenetic knowledge of drug metabolism and transport.Pregnane X receptor and yin yang 1 contribute to the differential tissue expression and induction of CYP3A5 and CYP3A4.Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics.P-Glycoprotein- and cytochrome P-450-mediated herbal drug interactions.A comprehensive investigation on common polymorphisms in the MDR1/ABCB1 transporter gene and susceptibility to colorectal cancer.Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease?Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation.Overcoming drug resistance by regulating nuclear receptors.Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR.Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs.Induction of P-glycoprotein in lymphocytes by carbamazepine and rifampicin: the role of nuclear hormone response elements Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters.Polymorphisms in the ABC drug transporter gene MDR1.Drugs as P-glycoprotein substrates, inhibitors, and inducers.Sucralose, a synthetic organochlorine sweetener: overview of biological issues Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein)Predicting inductive drug-drug interactions.Implications of pharmacogenetics for individualizing drug treatment and for study design.Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo

P2860

Q24599421-D8936A70-20F9-48C7-A5DA-1775B37E172F Q24656624-B460E0E6-30A4-4B92-A817-D7791480EE75 Q25255438-8A9E313A-E2FC-4F74-AA86-412781E54BE7 Q28071292-0D8F7552-F49A-4675-96F8-A4318CA636E2 Q28211706-2757AB2C-7154-4A8B-AC2A-BCA97CD285A0 Q28269209-75FBFD94-D415-4F37-9E2F-14F0D4C20EE8 Q28366014-A3058ADF-B922-47D3-84C8-27A6EA42CDB2 Q28481547-E90A0FF1-9CA3-4498-B390-F80C447AF69F Q28535627-C08033E5-19D7-45C4-BDDD-A74593D3D085 Q28551177-8A5FEB1B-4272-4D8E-B5E8-27FA9B4193E3 Q30478126-36B202DE-FC1C-4C45-9EC8-B396C2B780CA Q30571118-3B52091C-E93B-4E6E-ADCE-CB05B425E549 Q31043972-B3B338DB-34DE-442D-BE3F-3C98C5E968A1 Q33204911-AC256013-C152-433A-BB62-AEF5A6B3D7A2 Q33423486-97EC82C4-F780-46B4-B915-7BF5D9BE3BAD Q33805141-2F3B4A70-BA79-43AB-B472-B69459FCCC56 Q33867468-6B6392DA-B1F0-484C-ABF1-659917266B0B Q33938893-A5C99D79-4232-4679-9DB4-58351E6DF0EB Q33947052-AF6C7B5B-F371-4298-AFDE-E5039E3F41DB Q34018799-F7B82C06-E863-4102-8078-CE941B044723 Q34049823-E7E7B542-435A-473E-8078-03137955FCD6 Q34093093-86E41CB3-ED72-498B-BBE3-7EDF199165F3 Q34146529-9A60CEF1-CD08-4F04-BD73-026DE7B5590A Q34149022-74B609F0-587C-4310-B2E9-BAB52B440A05 Q34171741-CE1F7238-CD94-4337-BEA5-C0063F919EE0 Q34187283-DAD53940-CBF2-410B-AF96-0051D3E7C74C Q34190195-2FD2328A-3CD6-434D-8E15-0FE1AC33ABD2 Q34303346-15BD91F8-1765-4D33-8306-D757A57CE9D2 Q34349313-F1EC649E-40F7-4330-BFE5-8A7B5E47C840 Q34349336-E4BD876C-43F7-47CC-B09B-88D15CBC0351 Q34448305-CE7BF12F-EEA3-4F69-A345-465450CCBE86 Q34547632-3F18F988-2233-4297-BE2E-D3F513F98367 Q34568808-CD5B365C-5144-478E-A4ED-F631B78F4E89 Q34576932-057645A1-16F5-4F55-B189-AC4359BAF1FA Q34627908-E60A71BF-AA5F-4331-841E-C3D43C9554D3 Q34657381-92FEB80E-3847-45FD-93A8-2A9D004CDDE6 Q34994901-60463B5A-6524-4364-BFAB-6EF045A1D103 Q35073283-7BD6F88E-57BD-409B-955A-01097EED263D Q35102211-6175E465-A622-4575-8BDE-5423F80458A1 Q35113118-9467941C-E544-454D-B515-610AEF713637

P2860

The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin.

http://www.wikidata.org/entity/Q40851439

description

1999 nî lūn-bûn

@nan

1999年の論文

@ja

1999年学术文章

@wuu

1999年学术文章

@zh-cn

1999年学术文章

@zh-hans

1999年学术文章

@zh-my

1999年学术文章

@zh-sg

1999年學術文章

@yue

1999年學術文章

@zh

1999年學術文章

@zh-hant

name

The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin.

@en

type

label

The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin.

@en

prefLabel

The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin.

@en

P1433

Q40851439-8427E83A-EF65-4CF0-A85E-A9560891D3C1

P1476

Q40851439-27DF715E-4305-4C4C-ADB8-42C6F8475AEE

P2093

Q40851439-397E4513-A946-4E8E-9453-648E2E83910C

Q40851439-751AB55C-75D7-47E9-945A-3EC031541011

Q40851439-79BDDBFB-8B60-4237-9F82-7D339C61CC0D

Q40851439-BFD686B0-197C-4600-A380-DC3710BC4D4E

Q40851439-CB64EDDD-6827-45A7-8C10-3EEF002F2616

Q40851439-CD32824C-328E-4A84-8E37-8EEB7B69D7D7

Q40851439-F5C99DDA-5520-46B6-85D7-1A49367F01A8

P2860

Q40851439-043362F3-E1AF-4284-9A93-60F4BF07D646

Q40851439-0DCCD0A5-12C4-43C1-8D97-C66251034588

Q40851439-13827156-2241-4FAD-BA3C-5F4F3253F83B

Q40851439-14957258-711D-4566-B224-5F074BCA4072

Q40851439-17B61E6E-20B8-4E26-B674-ECEDDCA4AFAB

Q40851439-2F38450E-3F25-4540-923A-D0D8B5BBF034

Q40851439-39F72089-1642-42DD-ABE9-8BA4E8502AB8

Q40851439-4147EFBD-AEA4-4C65-A86E-965F0F244331

Q40851439-445073FD-FFBB-49F4-BDD5-E7C8EE355B6D

Q40851439-5646921D-EFB5-4602-B34D-551EF1508530

P304

Q40851439-05A87A28-20B0-458D-9B11-86CBEE492019

P31

Q40851439-12AEA537-7F5D-4F66-870E-7C249EE41198

P356

Q40851439-FD8251FF-EE28-45A5-8F19-E4695AE223D8

P407

Q40851439-69277CB6-833F-4727-B689-C068F296ED00

P433

Q40851439-C1BBB8B0-147B-43DD-AFF4-FE74BA388532

P478

Q40851439-8D92DABC-3770-4C7D-8A9C-227B9A748955

P577

Q40851439-F88E69EB-BE06-4541-95FC-6618869FD234

P5875

Q40851439-71B65732-ED76-43A2-888D-243D172F5870

P698

Q40851439-BEC2ED70-8CF6-48F5-8F4B-6379C0963491

P921

Q40851439-50DBE918-731C-42E9-8A6E-6242C0D5A277

P932

Q40851439-FB6DCF25-F67D-42D8-86F1-F0465CAA3486

P356

P1433

Journal of Clinical Investigation

P1476

The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin.

@en

P2093

B Greiner

http://www.w3.org/2001/XMLSchema#string

H K Kroemer

http://www.w3.org/2001/XMLSchema#string

H P Kreichgauer

http://www.w3.org/2001/XMLSchema#string

J Zundler

http://www.w3.org/2001/XMLSchema#string

M Eichelbaum

http://www.w3.org/2001/XMLSchema#string

O von Richter

http://www.w3.org/2001/XMLSchema#string

P Fritz

http://www.w3.org/2001/XMLSchema#string

P2860

Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues

Measurement of protein using bicinchoninic acid

Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833

The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.

Digoxin-rifampin interaction.

Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes

Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein

Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine

Characterization of a new monoclonal antibody F4 detecting cell surface epitope and P-glycoprotein in drug-resistant human tumor cell lines.

Structure and function of P-glycoprotein in normal liver and small intestine.

P304

147-153

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI6663

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

104

http://www.w3.org/2001/XMLSchema#string

P577

1999-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12887015

http://www.w3.org/2001/XMLSchema#string

P698

10411543

http://www.w3.org/2001/XMLSchema#string

P921

P932

408477

http://www.w3.org/2001/XMLSchema#string